Maze Therapeutics, Inc. (MAZE) stock
Close on Nov 11, 2026Market cap $2.04BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $2.04B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.76
- Dividend yield
- –
- Free cash flow yield
- -5.65%
Fundamentals
- Net income
- -$151.47M
- EPS, diluted
- -$2.65
- Free cash flow
- -$115.26M
- Book value per share
- $7.04
- Diluted shares
- 61M
Trading
- Next earnings
- Mar 24, 2027 (estimated, before the open)
- Previous close
- $35.45
- Open
- $35.38
- Day's range
- $35.38 – $37.41
- Volume
- 484,135
- Average volume (20 days)
- 689,051
- Index membership
- Russell 2000 (since Mar 2025), Russell 3000 (since Nov 2025)
- 52-week range
- $21.95 – $53.65
- RSI (14 days)
- 73.8
- Volatility (1 year)
- 67.1%
- Relative volume
- 0.79×
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MAZE | S&P 500 | Difference | MAZE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +35.5% | -2.4% | +37.9 pts | ||
| 3 months | +34.5% | -1.2% | +35.6 pts | ||
| Year to date | -11.3% | +12.3% | −23.6 pts | ||
| 1 year | +13.9% | +12.4% | +1.4 pts |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Maze Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- News
- Results
About Maze Therapeutics
Biological Products, (No Diagnostic Substances)
Maze Therapeutics is a clinical-stage biopharmaceutical company that develops small molecule precision medicines for individuals affected by kidney and metabolic disorders. The company identifies and characterizes genetic variants through its proprietary Compass platform to understand disease risk and guide drug development. Its pipeline includes investigational candidates such as MZE829, an oral inhibitor targeting APOL1-mediated kidney disease, and MZE782, alongside partnered assets like MZE001. The company focuses on patient populations suffering from conditions such as chronic kidney disease and engages biopharmaceutical collaborators through licensing agreements.
Company profile, executives and historyMaze Therapeutics stock: common questions
What is Maze Therapeutics's stock price?
MAZE closed at $36.73 on Nov 11, 2026, up 3.61% on the day. Over the past 52 weeks it traded between $21.95 and $53.65.
What is Maze Therapeutics's market cap?
Maze Therapeutics was worth $2.04B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MAZE's P/E ratio?
Maze Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.65), so it has no meaningful P/E ratio.
Does Maze Therapeutics pay a dividend?
No. Maze Therapeutics has not paid a cash dividend over the last twelve months.
When does Maze Therapeutics report earnings next?
Maze Therapeutics is expected to report Q4 FY2026 results on Mar 24, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has MAZE stock performed over the past year?
Including dividends, MAZE returned +13.9% over the past year, against +12.4% for the S&P 500.
How many MAZE shares are sold short?
7M shares were sold short at the latest FINRA report, 14.47% of the float, or 8.8 days of average trading volume.
Who are Maze Therapeutics's competitors?
Companies most similar to Maze Therapeutics by business, industry and size include KYMR, FDMT, BEAM, MGTX, ALEC.
See a number that looks wrong?